News and Announcements
Dimerix (ASX:DXB) releases positive results from Phase 2 Trial of DMX-200
- Published July 12, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Dimerix (ASX:DXB) is a clinical stage Australian Biotechnology company developing and commercialising novel drug therapies targeted at unmet patient needs, with the lead phase II clinical program (DMX-200) targeting chronic kidney disease. The company has recently announced “positive safety and efficacy data” following the company’s 27 patient Phase 2a Proof of Concept.
KEY TAKEAWAYS:
- Phase 2a of clinical trial tests has meet the primary safety checklist and demonstrates the efficacy in a number of patients.
- 25% of patients achieved a greater than 50% reduction in proteinuria.
- 45% of patients attained the permission to continue ongoing treatment.
- Study data informs dosing of patients and targeting parameters to progress the DMX-200 Phase 2b study during 2017.
Associate Professor David Packham* , one of the Principal Investigators in the study and Director of the Melbourne Renal Research Group, said “These are very encouraging data. DMX-200, and its combination with existing best therapy, appears safe and was well tolerated. An incremental 50% fall in proteinuria is a ‘high bar’ to set in studies of this type and the observation of this efficacy endpoint in 25% of the patients certainly warrants further clinical investigation in a larger, more targeted, population.’
Dimerix CEO Kathy Harrison said, “We are delighted that this study has resulted in such positive outcomes. The clinically meaningful reductions in proteinuria are highly encouraging and support the rationale behind the program. Given this is a “hard to treat” patient group, we now have a very strong indication that the treatment is having a significant impact in slowing the progression of Chronic Kidney Disease.
Company Updates
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
